RxDoctor Payments Data

Kerry Taveira

Psychiatric/Mental Health · Swansea, MANPI 1447222856

Payments from drug & device makers

$3,965in general payments, 2019–2025

Across 273 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$939
  • Otsuka America Pharmaceutical, Inc.$520
  • Alkermes, Inc.$470
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$410
  • Vanda Pharmaceuticals Inc.$256
  • Lundbeck LLC$253
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,87198%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,965 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$38,818
Medicare patients
41
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$167,047
VraylarCariprazine Hcl51$80,352
Lurasidone Hcl36$23,103
CaplytaLumateperone Tosylate11$20,843
TrintellixVortioxetine Hydrobromide11$5,498
Lisdexamfetamine Dimesylate14$5,327
Bupropion XlBupropion Hcl63$4,967
Quetiapine Fumarate181$3,282
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine55$2,145
Imipramine Pamoate12$1,831
Vilazodone Hcl20$1,780
Mirtazapine72$1,635
Buspirone Hcl82$1,532
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine31$1,467
Quetiapine Fumarate ErQuetiapine Fumarate12$1,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$233$167,04721 claims
AbbVieVraylar$939$80,35251 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$410$20,84311 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$71$5,49811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Swansea

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →